CSTL · Castle Biosciences, Inc.

The thesis

Castle Biosciences' recovery depends on TissueCypher, its test for Barrett's esophagus, growing volume 50–52% this year while the company holds its raised 2026 revenue range of $365–375 million. The third-quarter report settles it. MarketBeat estimates that report for 2 November 2026. A search on 9 October 2026 found no announced date. The company reported its third quarter of 2025 on 3 November 2025.

Nothing in the business has changed since the last update. The shares closed at $33.71 on 8 October 2026, a little above the $33.36 close of 6 October 2026, when they fell 8.98% without a company release, according to adjusted daily closes. The 8 October 2026 close sits 21.7% below the 52-week high of $43.04. The shares are still up 46.7% over three months. No guidance change, filing or new analyst action has appeared since management called the 2026 outlook unchanged at the Baird conference on 15 September 2026.

The narrative is maturing: the TissueCypher story is well known, and since 15 September 2026 company news has been clinical data, a publication and the 6 October 2026 opening of a Scottsdale laboratory, with no commercial update. The case now waits on the Q3 numbers.

Bullish and bearish views on Castle Biosciences, Inc.

The bull case on Castle Biosciences, Inc. (CSTL), in brief: TissueCypher volume carries the growth. The bear case: Growth is concentrated in one test.

Bull case

• TissueCypher volume carries the growth. Castle reported 14,988 TissueCypher tests in Q2 2026, up from 9,170 a year earlier. Total revenue was $103.5 million against $86.2 million, in results published 30 July 2026. Q2 results
• Guidance was raised, then reaffirmed. On 30 July 2026 Castle lifted 2026 revenue guidance to $365–375 million from $345–355 million. It also guided to positive adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) for Q3, Q4 and the full year. Management called the outlook unchanged at Baird on 15 September 2026.
• New Barrett's data supports adoption. A 699-patient decision-modeling study, released 15 September 2026, found that TissueCypher results would raise appropriate Barrett's esophagus management from 59.8% to 75.3%.
• The melanoma test gained outcome data. Castle's 30 September 2026 release covered a 2,799-patient, 29-center DecisionDx-Melanoma study for the European Academy of Dermatology and Venereology (EADV) Congress. Low-risk patients had 4.4% sentinel lymph node (SLN) positivity among the 676 biopsied. Among the 565 who skipped the biopsy, five-year recurrence-free survival was 99.6%.
• Analyst targets sit above the last close. MarketBeat's consensus target was $42.00 across 10 analysts as of 6 October 2026, with a range of $35 to $52. Roth MKM reiterated a $50 target on 22 September 2026, per Benzinga. MarketBeat

Bear case

• Growth is concentrated in one test. In Q2 2026, DecisionDx-Melanoma volume rose 3% from a year earlier, DecisionDx-SCC fell 16% and MyPath Melanoma fell 9%, according to the 30 July 2026 results. If TissueCypher slows, little else is growing.
• The pricing tailwind is fading. On the 30 July 2026 earnings call, management said the stepwise rise in TissueCypher average selling price seen in the first half of 2026 is not expected to repeat in the second half. Second-half revenue leans harder on volume.
• The squamous cell test lost Medicare coverage. DecisionDx-SCC reports fell to 4,011 in Q2 2026 from 4,762 a year earlier, after the 2025 Medicare coverage change. No reinstatement date has been published.
• Insiders have been selling into the rally. SEC Form 4 filings summarized by MarketBeat show about $6.0 million of insider sales over three months to 6 October 2026 and no purchases.
• Profitability is adjusted, not reported. Q2 2026 showed a $2.1 million GAAP net loss alongside $12.4 million of adjusted EBITDA.

Price setup

The shares closed at $33.71 on 8 October 2026. That is 21.7% below the 52-week high of $43.04 and 46.7% above the level of three months earlier, per adjusted daily closes. The 14-day relative strength index stood at 41.2, a reading that shows momentum has cooled without reaching oversold territory.

The August recovery began from a $29.62 close on 14 August 2026. That close is the nearest marked low under the current price. The single-day drop on 6 October 2026, from $36.65 to $33.36, came with no company news.

Crowding is moderate. Short interest was 6.62% of float on MarketBeat as of 6 October 2026. Insider selling has continued through 10b5-1 plans, and the Q3 report falls about three and a half weeks out, so an earnings move is inside the next month.

Catalysts, next 30 days

• ~2 November 2026 (est.): Q3 2026 results. The report tests the 50–52% TissueCypher volume guidance, the $365–375 million revenue range and the promised positive Q3 adjusted EBITDA. It also shows whether DecisionDx-Melanoma growth has moved beyond the 3% printed in Q2. MarketBeat's estimate; the company has not announced a date.
• Undated: Medicare update on DecisionDx-SCC. A coverage decision from the Centers for Medicare & Medicaid Services and its MolDX program has no published timetable. Reinstatement would add revenue that current guidance does not assume.

What would change the view

The case breaks if the Q3 report lowers 2026 revenue guidance below $365 million or TissueCypher volume-growth guidance below 50%. A zero or negative adjusted EBITDA figure for Q3, after the 30 July 2026 promise of a positive quarter, would also break it.

On price, a weekly close below $29 would put the shares under the $29.62 close of 14 August 2026 and erase the August recovery.

The case would strengthen if Q3 revenue tracks the top of the range and DecisionDx-Melanoma volume growth rises clearly above the 3% reported for Q2. That would ease the single-test concentration.

What it trades with

The shares trade on company-specific volume, pricing and reimbursement news. The 6 October 2026 drop arrived with no sector move cited in coverage. The closest comparables are other molecular diagnostics laboratories whose revenue depends on Medicare coverage decisions and on commercial payers' prices. As a small-cap healthcare name, the stock is also exposed to broad small-cap risk appetite. The Q3 report is the dominant driver over the next month.